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Abstract
This paper estimates the income elasticity of government pharmaceutical spend-
ing and assesses the simultaneous effect of such spending on gross domestic prod-
uct (GDP). Using a panel dataset for 136 countries from 1995 to 2006,we employ a
two‐step instrumental variable procedure where we first estimate the effect of
GDP on public pharmaceutical expenditure using tourist receipts as an instru-
ment forGDP. In thesecondstep,weconstructanadjustedpharmaceutical expen-
diture series where the response of public pharmaceutical expenditure to GDP is
partialled out and use this endogeneity adjusted series as an instrument for phar-
maceutical expenditure. Our estimations show that GDP has a strong positive
impact on pharmaceutical spending with elasticity in excess of unity in countries
with low spending on pharmaceuticals and countries with large economic free-
dom. In the second step, we find that when the quantitatively large reverse effect
of GDP is accounted for, public pharmaceutical spending has a negative effect
on GDP per capita particularly in countries with limited economic freedom.
KEYWORDS
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1 | INTRODUCTION
This paper confronts two questions related to medical spending. First, the paper estimates the income elasticity of
government pharmaceutical spending, and second, it assesses the simultaneous effect of such spending on income
itself. Both questions are important from a health economics and a public spending perspective. The rise in health
expenditures in the latter half of the 20th century has increased fiscal constraints for governments worldwide. Policy
makers therefore are keen on understanding the determinants of health expenditure to identify the right policy
levers that can address budgetary concerns. Concurrently, the understanding of the impact of such spending on eco-
nomic growth itself is limited. The effect of government spending on economic growth has been a central issue in
the growth literature for more than 30 years (Aschauer, 1989; Barro, 1990; Landau, 1983). It is widely recognized
that increasing or decreasing government expenditures should be informed on the basis of the contribution of each
spending component to economic growth (Devarajan, Swaroop, & Zou, 1996).
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There is a voluminous literature that tackles both these issues, yet these questions remain open for further research for
several reasons. First, findings from previous literature remain inconclusive concerning themagnitude of the income elas-
ticity of health spending. Some studies argue that health expenditure is a luxury good (Kleiman, 1974; Leu, 1986;
Newhouse, 1977) whereas others find it to be a necessity good (Baltagi & Moscone, 2010; Di Matteo, 2003; Farag et al.,
2012; Moscone & Tosetti, 2010; Parkin, McGuire, & Yule, 1987). Though findings from past literature thus disagree with
respect to the magnitude of the relationship, they concur concerning the sign of the coefficients in that national income
relates positively with health expenditure (see, among others, Barros, 1998; Hauck & Zhang, 2016; Hitiris & Posnett,
1992; Getzen, 2000; Xu, Saksena, & Holly, 2011).
The lack of consensus in the elasticities can be attributed to both theoretical and methodological differences. On the
theoretical front, micro econometric analyses of health expenditures rely on standard demand theory and find elasticities
less than unity. Macro level analyses usemodels similar in theory to those used bymicro studies but find elasticities greater
than unity (Gerdtham & Jönsson, 2000). Applying standard demand theory to aggregated data may therefore not be suit-
able because a nation's income constraint may be more binding than that of an individual, particularly in countries where
the state is largely responsible for health care costs (Gerdtham & Jönsson, 2000; Moscone & Tosetti, 2010). On the meth-
odological front, the incongruence in the estimates from different studies arises due to functional form differences in the
econometric models, use of different conversionmetrics for expenditure and income data, and unaccounted heterogeneity
(see,e.g., Getzen, 2000; Gerdtham & Jönsson, 1991; Gerdtham & Jönsson, 1992; Parkin et al., 1987). Further, first genera-
tion studies largely relied on cross sections of countries whereas second‐generation studies employedmore rigorous econo-
metric methods such as panel data analyses, thereby controlling for several sources of endogeneity (see Gerdtham &
Jönsson, 2000, for a detailed overview of these). Despite the research efforts, it is therefore still an open debate whether
health care is a luxury good or a necessity good. With regard to The Organisation for Economic Co‐operation and
Development (OECD) countries, some papers report that income elasticity is larger than unity, that is, health care is
a luxury good (e.g., Gerdtham & Löthgren, 2002; Okunade & Murthy, 2002), whereas others state that the elasticity
is less than unity, that is, health care is a necessity good (e.g., Baltagi & Moscone, 2010; Bilgel & Tran, 2013; Dreger
& Reimers, 2005; Freeman, 2003). In studies on developing countries, the results also diverge. For example, Bhat and
Jain (2004), Jaunky and Khadaroo (2008), and Mehrara and Musai (2011) report income elasticities larger than one,
whereas Sahn (1992) among others provides evidence that the income elasticity is less than one. Owing to the differential
findings, the income elasticity of health spending remains an open question.
Moreover, past literature has largely focused on total health expenditures, ignoring the different components it
comprises. It seems plausible to presume that the elasticity of health spending will depend on the very component
of spending being considered. As such, the source of variation in health expenditure matters for the income elasticity
of expenditures (Acemoglu, Finkelstein, & Notowidigdo, 2013). To the best of our knowledge, there is no country
level analysis that explores the income elasticity of public pharmaceutical expenditures in both high‐ and low‐income
countries.1 This seems surprising because there are several reasons why this type of spending should be of particular
interest. First, it forms a large part of total health expenditure and has increased by almost 50% since 2000 (OECD,
2011), which has exposed it to several regulations and cost containment measures. Second, policy makers are endors-
ing the view that savings can be achieved by regulating pharmaceutical markets and reducing costs without affecting
the quality of care (Carone, Schwierz, & Xavier, 2012). Finally, income elasticity of pharmaceutical spending has
important implications in terms of pharmaceutical policy itself.
With respect to the second question of our paper, the effect of public pharmaceutical spending on economic
growth, the question is of interest from different perspectives just as the answer remains ambiguous from these per-
spectives. From a health economics perspective, inasmuch as spending on health leads to improved health outcomes,
a positive relationship between health spending and economic growth can be expected. Although some papers find a
positive link between health and economic growth (Bloom, Canning, & Sevilla, 2004), others find no effect of health
on growth (Acemoglu & Johnson, 2007; Ashraf, Lester, & Weil, 2008; Hansen & Lønstrup, 2015). The effect of health
spending therefore remains questionable. From a pure public spending perspective, findings from the literature also
add to the debatable effects of health spending on gross domestic product (GDP). Some of the previous literature
finds a negative relationship between excessive public spending and GDP (Devarajan et al., 1996; Miller & Russek,
1Acemoglu et al. (2013) assess the response of hospital expenditures to income and further break it down into payroll expenditure, employee expen-
ditures, skill composition, hospital utilization, etc.
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1997) whereas others consider health spending a “productive” form of public expenditure that affects growth posi-
tively (Bleaney, Gemmell, & Kneller, 2001; Glomm & Ravikumar, 1997).2
Therefore, in this paper, we assess the effect of income measured in GDP per capita on public pharmaceutical expen-
diture per capita and the reverse effect using a sample of 136 countries from 1995 to 2006. We use a relatively recent two‐
step instrumental variable (IV) procedure (from the aid effectiveness literature; see Brückner, 2011) to assess the causal
effect of GDP on pharmaceutical spending in the first step and then assess the effect of pharmaceutical spending on
GDP in the second step after accounting for the simultaneous effect of GDP from the first step. We find that the income
elasticity of public pharmaceutical expenditure is greater than unity in the full sample, and that there is a negative effect
of public pharmaceutical expenditure on GDP per capita. However, important heterogeneous patterns exist. GDP per
capita has a statistically significant positive effect on pharmaceutical spending only for high‐income countries, and phar-
maceutical spending has a statistically significant negative effect only for low‐income countries. Quantile regressions show
that the income elasticity of pharmaceutical spending varies across the distribution of pharmaceutical spending. Similarly,
the negative effect of pharmaceutical expenditure on GDP is statistically significant only for the middle (25th, 50th, and
75th) quantiles of income. Finally, based on the index of Economic Freedom of the World (EFW) by the Fraser Institute,
we find that GDP per capita does not have an effect on pharmaceutical expenditure in countries that are classified as “not
free.”However, pharmaceutical spending has a statistically significant negative effect onGDP per capita in these countries.
Our paper contributes at several levels. First, it contributes directly to the literature that assesses the effect of public
spending on economic growth. Although there is some literature on the effect of total health expenditure, we found no
paper specifically analyzing public spending on pharmaceuticals. This paper attempts to fill that gap. Second and more
importantly, our contribution to the literature in health economics is twofold by—(a) assessing the income elasticity of
public pharmaceutical spending across a multitude of countries using IVs, something which past studies have not con-
sidered,3 and (b) assessing the effect of pharmaceutical spending on a nonhealth outcome such as economic growth.
The paper is organized as follows. In Section 2, we discuss the econometric methodology. Section 3 introduces the
data and presents descriptive statistics. In Section 4, we present and discuss our findings along with different sensitivity
tests. Section 5 revisits instrument validity, and Section 6 presents results of the heterogeneity analysis. Section 7 dis-
cusses the effect of pharmaceutical expenditure on GDP, and Section 8 concludes with policy implications.
2 | ECONOMETRIC FRAMEWORK
To assess the effect of GDP per capita on public pharmaceutical spending per capita and the reverse effect within the
same econometric framework, we employ a two‐step IV procedure outlined in Brückner (2011) and Moreno‐Serra
and Smith (2015).4 Throughout the remainder of the paper, GDP refers to GDP per capita and pharmaceutical expen-
diture refers to public pharmaceutical expenditure per capita. In the first step, we assess the causal effect of GDP on
pharmaceutical expenditure using an IV approach. In the second step, because we are also interested in estimating
the effect of pharmaceutical expenditure on GDP, we generate a new endogeneity adjusted pharmaceutical expenditure
series using the residual variation in pharmaceutical expenditure from the first step (where the response of pharmaceu-
tical spending to GDP is partialled out). We describe the two‐step procedure in detail now.
Step 1: Estimating the causal effect of GDP on pharmaceutical expenditure.
2We acknowledge that in order to understand the full picture of the response of pharmaceutical spending to GDP growth and vice‐versa, an analysis of
total pharmaceutical expenditures and not just the public component of it is essential. This is particularly relevant for low‐income countries where
public spending levels are low and private spending is an important method of financing. However, we are limited in our analysis owing to data con-
cerns with respect to private spending that is part of total spending. Certain components are not included in total spending such as medicines covered
by private insurance, produced by local pharmacists and hospitals, and informal sales or payments (e.g., unregistered or resale pharmaceuticals). These
largely represent private spending in low‐income countries that would be heavily underestimated. Moreover, we consider the question of how private
spending on pharmaceuticals affects growth only of relevance if it were an option to contain private spending. Yet, based on the values of a democratic
society and its public discourse, citizens shall not be prohibited from purchasing pharmaceuticals in a private market if these pharmaceuticals are not
covered by their insurance. That is, based on democratic values strict rationing seems hardly defendable and requires enforcement, rendering the ques-
tion of whether to contain private spending essentially a hypothetical one.
3Farag et al. (2012) and Acemoglu et al. (2013) are notable exceptions that used instrumental variables. However, their dependent variables were
different.
4To the best of our knowledge, Moreno‐Serra and Smith (2015) are the only other authors within health economics to have used the two‐step IV
procedure.
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Consider the following regression specification:
Yit ¼ βXit þ μWit þ αi þ γt þ εit; (1)
where the subscripts i and t represent country and time, respectively. Yit is the dependent variable (public pharmaceu-
tical expenditure per capita) to be explained by Xit, which is the variable of main interest (GDP per capita). Wit is a vec-
tor of time varying controls that is included in the specification along with a full set of country dummies αi that capture
the effect of time‐invariant unobservables, and a full set of time dummies γt aimed at capturing common shocks to the
countries. εit represents the error term that captures all sources of endogeneity.
5 Although fixed effects may serve as a
useful framework to overcome time‐invariant unobserved heterogeneity, two sources of bias remain and therefore
Cov(Xit, εit) ≠ 0. First, time varying unobserved variables (omitted variables) are particularly concerning because these
have the potential to upward or downward bias the estimates. Second and more crucial is the reverse causal effect of
pharmaceutical expenditure itself on GDP, which can lead to an upward bias in Equation 1 if pharmaceutical expendi-
ture is positively related to GDP. In order to overcome these issues and to appropriately estimate the effect of GDP on
pharmaceutical expenditure, we need an instrument Zit that is correlated strongly with Xit (i.e., GDP; condition of rel-
evance) and is excluded from the second stage (exclusion restriction).
We use international tourist receipts as an instrument for GDP. International tourist receipts reflect expenditures by
international inbound visitors. These are, as defined by the World Tourism Organization, receipts earned by the desti-
nation country and cover spending on lodging, food and drinks, fuel, transport, entertainment, shopping, etc. The rela-
tionship between tourism and the economy is intuitively straightforward. Tourism directly or indirectly generates an
increase in economic activity and results in an increase in the wealth of the residents through, for instance, the services
they provide and employment. As such, it should be positively related to the GDP of a country. The tourism led growth
hypothesis has been extensively tested and supported in the tourism‐growth literature (Brida & Pulina, 2010; Brida,
Risso, Lanzilotta, & Lionetti, 2010; Gunduz & Hatemi‐J, 2005; Lean & Tang, 2009; Risso & Brida, 2009). Although
the instrument easily satisfies the relevance criteria as shown by the first stage results and F‐statistics that are well
beyond the conventional benchmark of 10, we argue for the validity of the IV in what follows.
Our exclusion restriction requires that Cov(Zit, εit|Wit,αi, γt) = 0, that is, international tourist receipts be unrelated to
public pharmaceutical expenditure except through GDP. We do not fathom why tourist expenditures should be related to
public pharmaceutical expenditures or should have a substantial effect on them that should be of concern. However, one
possible threat to the instrument is the existence and extent of medical tourism in a country. Even then, we posit that this
should at least not be related to “public” pharmaceutical expenditures of a country, because a medical tourist will in gen-
eral pay for his health care privately. Even if insurance pays for the tourists, it should be reflected in the expenditure of
the home country. We also conduct other tests in support of our instrument, which are discussed in Section 6.
Step 2: Estimating the effect of pharmaceutical expenditure on GDP.
Now consider a reverse econometric framework of Equation 1
Xit ¼ δYit þ μWit þ αi þ γt þ εit: (2)
If GDP has a significant causal effect on pharmaceutical spending estimated from Step 1, then the ordinary least
squares estimate of the effect of pharmaceutical expenditure on GDP will suffer from this endogeneity bias, that is,
Cov(Yit, εit) ≠ 0. This endogeneity bias however can be taken care of by constructing an adjusted pharmaceutical spend-
ing series (Y *it in Equation (3) below) where the response of pharmaceutical spending to GDP is partialled out, that is,
Y *it ¼ Yit − βXit: (3)
This endogeneity adjusted pharmaceutical expenditure series is free of the simultaneity bias due to GDP by construc-
tion. Using the residual variation in expenditure that is not driven by GDP as an instrument for pharmaceutical expen-
diture in (1) adjusts for the reverse causality and provides a consistent estimate. This procedure assumes that the
5The choice of a fixed effects model is motivated by the fact that there could be omitted variables (time‐invariant and time varying) that relate to both
pharmaceutical expenditure and GDP. For example, geographic location may have a strong impact on disease burden and on economic growth
(Boulhol, de Serres, & Molnar, 2008; Gallup, Sachs, & Mellinger, 1999). The assumptions of a random effects model are, therefore, not satisfied. Nev-
ertheless, we report results of the Hausman tests in Table 2, which support fixed‐effects specifications.
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exclusion restriction in (1) holds, that is, error terms in (1) and (2) are uncorrelated. If there are omitted variables that
are part of both Equations 1 and 2, then the correlation between the two error terms is likely. However, the procedure
will still solve the reverse causality problem and provide consistent estimates (see Brückner, 2011, for details on the
procedure). It is important to mention here that there will be correlation between the error terms of the two equations
only if there are omitted variables that will affect the within‐country changes in both GDP and pharmaceutical expen-
diture simultaneously. For this reason, we also include several time varying controls in Wit that may be important and
may determine both GDP and pharmaceutical expenditure along with country and time fixed effects that take into
account other unobservable heterogeneity related to country specific characteristics and common shocks, respectively.
3 | DATA AND DESCRIPTIVE STATISTICS
The data we use in this paper come from different sources. The data on pharmaceutical expenditures come from the
World Health Organization's World Medicines Situation 2011—Medicine Expenditures' annex. The data are publicly
available at http://apps.who.int/medicinedocs/en/d/Js20052en/ [Last accessed 23 February 2018]. The remainder of
the data that we use in our analysis comes either from the World Bank Open Data or from the International Monetary
Fund's World Economic Outlook database. The dataset we use is an unbalanced panel from 1995 to 2006 for a total of
136 countries. Therefore, we have around 1,389 observations in total with around 10 observations per country on aver-
age. The variables of interest are described in detail in the following.
Public pharmaceutical expenditure per capita comes from the World Health Organization (WHO) and is expressed
in U.S. dollars (at exchange rate). Comparability of expenditures between countries has been a key issue in past studies.
One of the advantages of this dataset is that it is based on a WHO methodology that promotes comparable country data
on health system expenditures. Total pharmaceutical expenditures that provide a measure of consumption of pharma-
ceuticals are disaggregated to reflect public and private expenditures. The data, however, do not distinguish between
generic or branded medicines and are regardless of the means or place of distribution. For a detailed overview of the
data, we refer readers to the World Medicines Situation 2011 report. In our analysis sample, average annual public phar-
maceutical expenditure per capita is $64 with a maximum of $832. For high‐income countries, it is $108 whereas for
low‐income countries it is $5. Table 1 shows the summary statistics for all variables for the overall sample and by
income group and Table A1 lists the countries used in the analysis.6 Later on in the analysis, we use the two‐income
groups as one way of assessing heterogeneity.
GDP per capita data are from the World Bank database and expressed in U.S. dollars based on purchasing power par-
ities. GDP per capita is a commonmeasure of economic growth and has been used extensively in the literature (some exam-
ples are Barro, 1991; Barro &McCleary, 2003; Bloom et al., 2004; Grossman &Krueger, 1995). The average GDP per capita
in our full sample is $13,584; for high‐income countries, it is $22,308, and for low‐income countries, it is $1,839.
The instrument, international tourist receipts, also comes from the World Bank database and is expressed in U.S. dol-
lars. As mentioned earlier, international tourism receipts are expenditures by international inbound visitors and were
found to have a strong positive relationship with economic growth by previous literature. As seen in the summary statistics
in Table 1, income from tourist receipts is much lower for low‐income countries compared with high‐income countries.
One can speculate that the contribution of tourist receipts to GDP may be heterogeneous based on income levels, and
hence, the first stage relationship between tourist receipts and GDP may be stronger for high‐income than low‐income
group of countries. Figure 1 shows the raw correlation of tourist receipts with GDP per capita per year. It can be seen that
the correlation between tourism receipts and GDP per capita is positive across all the years of the analysis. Our first stage
F‐statistics shown later in the results section are clearly above the thumb rule of 10 for both the income groups and for the
overall sample, thus alleviating the concern of a weak first stage relationship for the low income group.
We include a host of other variables in our analysis that could be possible sources of omitted variable bias in the
regressions. First, we control for health expenditure other than public pharmaceutical expenditure because it seems
likely that this may drive both GDP and public pharmaceutical spending. We also control for life expectancy at birth
as a measure of health at the country level. The direction in which health will bias the results is ambiguous a priori
because it may be either positively (Bloom et al., 2004; Bloom & Canning, 2000) or negatively (Acemoglu & Johnson,
2007; Ashraf et al., 2008; Hansen & Lønstrup, 2015) related to income. Although we are not interested in the effect
6Due to sample size issues, we pool high‐income and upper middle‐income countries into one group called “high‐income” countries and lower and
lower‐middle income countries into another group called “low‐income” countries.
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TABLE 1 Summary statistics
Variable
Full sample
Std. dev. Min MaxObs. Mean
Public pharmaceutical exp. per capita ($US) 1,389 64.12639 106.3668 0.041849 831.9869
GDP per capita ($US) 1,389 13583.8 17704.4 233.1437 103060.5
Remaining health exp. per capita ($US) 1,389 798.5446 937.5408 12.56647 6787.797
Tourist receipts (millions [$US]) 1,389 4.76E + 09 1.25E + 10 400000 1.27E + 11
Life expectancy at birth (years) 1,369 70.14461 7.928318 42.1582 82.32195
Gross savings (% of GDP) 1,175 20.94163 10.89711 −146.164 64.71603
Capital formation (% of GDP) 1,309 24.34591 12.91513 0 219.0694
Total government expenditure (% of GDP) 1,289 31.22698 12.44523 9.328 128.289
Population over 65 years (% of total) 1,365 8.537837 4.868295 2.198119 20.39357
High income
Variable Obs. Mean Std. dev. Min Max
Public pharmaceutical exp. per capita ($US) 797 107.9008 123.2819 1.442033 831.9869
GDP per capita ($US) 797 22307.84 19147.86 981.5044 103060.5
Remaining health exp. per capita ($US) 797 1257.722 1011.799 68.26747 6787.797
Tourist receipts (millions ($US)) 797 7.45E + 09 1.58E + 10 400000 1.27E + 11
Life expectancy at birth (years) 777 74.39379 4.87424 50.35488 82.32195
Gross savings (% of GDP) 709 21.95556 11.25445 −146.164 64.71603
Capital formation (% of GDP) 781 25.44211 15.1979 0.298644 219.0694
Total government expenditure (% of GDP) 751 35.91555 11.07614 11.77 128.289
Population over 65 years (% of total) 773 11.19371 4.541596 2.198119 20.39357
Low income
Variable Obs. Mean Std. dev. Min Max
Public pharmaceutical exp. per capita ($US) 592 5.19356 6.165289 0.041849 42.5232
GDP per capita ($US) 592 1838.763 1229.937 233.1437 5596.732
Remaining health exp. per capita ($US) 592 180.362 135.5475 12.56647 692.0238
Tourist receipts (millions ($US)) 592 1.15E + 09 3.34E + 09 800000 3.39E + 10
Life expectancy at birth (years) 592 64.56755 7.707776 42.1582 76.28613
Gross savings (% of GDP) 466 19.39897 10.14878 −14.3849 54.65947
Capital formation (% of GDP) 528 22.72446 8.229088 0 61.90938
Total government expenditure (% of GDP) 538 24.68214 11.24678 9.328 104.389
Population over 65 years (% of total) 592 5.069947 2.546296 2.420117 16.10646
Note. GDP: gross domestic product.
FIGURE 1 Gross domestic product
(GDP) and international tourist receipts
[Colour figure can be viewed at
wileyonlinelibrary.com]
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of health per se, it is necessary that we show robustness of our results to the inclusion of this variable. We also control
for variables that are considered important in the macro literature such as savings rate, demographic structure of the
country (population over 65 years of age), gross capital formation, and total government expenditures. Summary statis-
tics for all these variables can also be seen in Table 1. To interpret the estimates as elasticities, we take the log form of
both GDP and public pharmaceutical expenditure.
4 | MAIN RESULTS
4.1 | Effect of GDP per capita on public pharmaceutical expenditure
Table 2 shows the results of the effect of GDP per capita on public pharmaceutical expenditure per capita. Column (1) pre-
sents fixed effects estimates which show a significant positive relationship between GDP and pharmaceutical expenditure.
The magnitude of the coefficient indicates that pharmaceutical expenditure has an income elasticity of less than unity,
similar to the findings of some of the previous literature with respect to total health expenditures. However, these esti-
mates cannot be considered as reflecting the causal effect of GDP on pharmaceutical spending because these are riddled
with endogeneity problems discussed previously. Although the regression includes country and time fixed effects, thereby
accounting for fixed sources of heterogeneity, other issues with regard to time varying variables and reverse causality
remain. Hence, these estimates should be taken at face value simply for comparison purposes with the IV estimates.
Before presenting the IV estimates, we show the first stage relationship of the instrument and the endogenous variable.
Column (2) presents the results of the first stage relationship between tourist receipts and GDP per capita. The regression
results confirm the graphical evidence from Figure 1. In line with the “tourism led growth” hypothesis and findings of pre-
vious literature (Brida et al., 2010; Brida & Pulina, 2010; Gunduz & Hatemi‐J, 2005; Lean & Tang, 2009; Risso & Brida,
2009), we see that tourism expenditures by international inbound visitors are positively and significantly related to GDP
per capita. First stage R‐squared is high, indicating that the instrument fulfills the relevance criteria, and it provides esti-
mates in the direction that one would expect. Next, in column (3), we show the reduced form estimate, that is, the relation-
ship between the instrument and pharmaceutical expenditure. If the reduced form effect is not significantly different from
zero, the effect of interest can be presumed to be absent or the instrument too weak (Angrist & Krueger, 2001). Column (3)
TABLE 2 GDP per capita and public pharmaceutical expenditure per capita
Variables
(1) (2) (3) (4)
FE OLS First stage Reduced form 2SLS
Pharmaceutical
expenditure
GDP per capita
(natural log)
Pharmaceutical
expenditure
Pharmaceutical
expenditure
GDP per capita (natural log) 0.709*** (0.215) 1.406** (0.653)
Tourist receipts 0.0935*** (0.0240) 0.131** (0.0514)
Year FE Yes Yes Yes Yes
Country FE Yes Yes Yes Yes
Observations 1,389 1,389 1,389 1,389
R‐squared 0.476 0.563 0.458 0.445
First stage F‐stat 15.12
p value 0.0002
Kleibergen‐Paap LM statistic 9.97
p value 0.0016
Hausman test statistic 25.46 29.60 279.908 279.907
p value 0.0128 0.0000 0.0000 0.0000
Endogeneity test 2.37
p value 0.1232
No. of countries 136 136 136 136
Note. The DV in columns (1), (3), and (4) is public pharmaceutical expenditure per capita (natural log), whereas in column (2), it is GDP per capita (natural log).
Column (1) shows the fixed effects estimate of the effect of GDP per capita (natural log) on the DV. Column (2) shows the first stage relationship between GDP
per capita and the instrument tourist receipts (natural log). Column (3) shows the reduced form effect of the instrument on the DV. Column (4) shows the IV
estimate of the effect of GDP on the DV. DV: dependent variable; GDP: gross domestic product; IV: instrumental variable; OLS: ordinary least squares.
***p < 0.01. **p < 0.05. *p < 0.1.
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shows that tourist receipts have a statistically significant positive effect on pharmaceutical expenditure per capita in the
reduced form as one would have expected. Finally, in column (4), we present the two‐stage least squares estimate that uses
tourist receipts as an instrument for GDP per capita. The first stage F‐statistic is 15.12 (significant at a 1% level), indicating
that the instrument is strong enough to predict GDP. The Kleibergen‐Paap LM statistic is also strongly significant. The sec-
ond stage estimate of GDP per capita on public pharmaceutical expenditure is positive and significant at a 1% level, and the
magnitude of the coefficient is much larger than the least squares estimate in column (1). The larger coefficient size could
be due to a number of reasons. If there are unobserved variables that are negatively (positively) related to GDP and posi-
tively (negatively) related to pharmaceutical spending, a downward bias could be observed. For example, disease burden of
a country could lead to an underestimate of the true effect of GDP on pharmaceutical expenditure.7
Quantitatively, the IV estimate suggests that a 1% increase in GDP per capita increases public pharmaceutical expen-
diture per capita by 1.4%, implying that public pharmaceutical spending has an elasticity greater than unity and hence is
a luxury good. This two‐stage least squares estimate is causal to the extent that the exclusion restriction is satisfied, that
is, tourist receipts do not have any systematic relationship with public pharmaceutical expenditure other than through
GDP per capita. We further discuss the validity of the instrument later in Section 6.
4.2 | Robustness tests
To test the sensitivity of our results, we perform different robustness checks. First, issues around sample size and out-
liers are dealt with. Second, robustness of the point estimates is tested to the inclusion of other covariates that have the
potential to confound the relationship between GDP and pharmaceutical expenditure.8
Table 3 provides all these robustness checks. In column (1), we run regressions only on observations that produce
a balanced panel from 1995 to 2006. The point estimates of column (1) are similar in magnitude to those of column (4)
in Table 2. Next, in column (2), we exclude outliers from the balanced panel, identified using the Hadi (1992) proce-
dure. This leads to the exclusion of 363 observations. The point estimates are still positive and statistically significant
at a 10% level; however, the magnitude of the coefficient is now slightly higher. Further, in column (3), we include
variables deemed important in both the health and growth literature as controls in our models. Specifically, we control
for what we consider demand side variables such as health (proxied by life expectancy at birth) and demographic
structure of the population by controlling for population over the age of 65 years. On the supply side, we control
for health expenditure per capita excluding pharmaceutical expenditure and total government expenditure as a per-
centage of GDP. Variables considered important in the macro growth literature such as gross savings (as a percentage
of GDP) and gross capital formation (as a percentage of GDP) are also included as further control variables. In column
(4), we include these control variables along with the exclusion of identified outliers. In both cases, the coefficients are
qualitatively similar. The coefficients are significant at a 5% level in both columns (3) and (4) and the magnitudes well
above unity.
Finally, an important issue, also raised in prior analyses, relates to health expenditure inertia. It seems reasonable to
assume that current pharmaceutical spending depends on past spending behavior. Therefore, it becomes important to
assess robustness by accounting for this inertia in pharmaceutical expenditure. We run a dynamic model including
the lags of pharmaceutical expenditure in the regressions where we follow prior literature concerning the choice of
the number of lags. Okunade and Suraratdecha (2000) consider one lag as appropriate, whereas Moreno‐Serra and
Smith (2015) use up to two lags. For brevity, we show the results of the dynamic model in column (5) of Table 3 using
only one lag; however, we have also tested robustness using two lags of expenditure. The results are similar.
Overall, the point estimates are always above unity implying that pharmaceutical spending is a luxury good, which
is in contrast to findings from some of the recent studies that use panel data and assess the income elasticity of total
health expenditures (Baltagi & Moscone, 2010; Di Matteo, 2003; Farag et al., 2012; Freeman, 2003; Sen, 2005). Our
results therefore point out that different components of health spending may behave differently and exhibit different
7Note that the endogeneity test suggests that GDP per capita is exogenous; however, results presented in columns (3) and (5) of Table 3 below suggest
that it is indeed endogenous. In any case, we have outlined strong theoretical reasons and prior empirical evidence that leaves little contention
concerning the endogenous nature of economic growth. Moreover, in Step 2 of the empirical strategy where we assess the impact of pharmaceutical
expenditure on GDP, the test strongly suggests pharmaceutical expenditures as endogenous (see Table 4).
8In addition, to avoid generated regressor bias in step 2 of the analysis, i.e. the effect of pharmaceutical expenditure on GDP, we run these regressions
with bootstrapped standard errors to which the results remain robust. These results are available from the authors upon request.
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elasticity estimates. Therefore, policy makers should consider this heterogeneity before introducing measures targeting
health expenditures.
4.3 | Effect of public pharmaceutical expenditure on GDP per capita
Our second research question aims at assessing the effect of public pharmaceutical spending on economic growth.
We present the results here. The analysis so far suggests that public pharmaceutical expenditure is highly endog-
enous to GDP per capita. To be precise, the IV estimates suggest that per capita GDP has a strong positive effect
on public pharmaceutical spending per capita, which is both economically and statistically significant. Therefore,
an ordinary least squares estimation of the effect of public pharmaceutical spending on GDP will most likely be
upward biased if the reverse positive effect of per capita GDP on pharmaceutical expenditure is not addressed.
While controlling for unobserved heterogeneity in the form of fixed effects and several other confounders may
solve the problem of omitted variable bias to some extent, the bias due to reverse causality will still persist. We
therefore run our regressions as mentioned in Step 2 of the econometric framework (outlined in Section 2) where
the residual variation in public pharmaceutical expenditure is used as an instrument for public pharmaceutical
expenditure.
Table 4 presents results of the effect of public pharmaceutical expenditure per capita on GDP per capita. Column (1)
shows IV estimates using the full sample. We find that public pharmaceutical spending is negatively related to GDP per
capita. The estimate is significant at a 5% level and quantitatively means that a 1% increase in public pharmaceutical
expenditure is related to a 0.09% decrease in GDP per capita. Although this result seems counter‐intuitive to what most
TABLE 3 Robustness tests
Variables
(1) (2) (3) (4) (5)
Balanced panel Outliers (O) Controls (C) O + C C + L
Pharmaceutical
expenditure
Pharmaceutical
expenditure
Pharmaceutical
expenditure
Pharmaceutical
expenditure
Pharmaceutical
expenditure
GDP per capita (natural log) 1.654* (0.989) 2.046* (1.175) 2.566** (1.008) 1.878** (0.853) 1.953** (0.833)
Health expenditure −0.305 (0.317) −0.203 (0.255) −0.273 (0.264)
Life expectancy −0.621 (2.058) −0.299 (1.909) −1.039 (2.074)
Capital formation −0.00186 (0.00686) 0.00195 (0.00864) −0.00254 (0.00398)
Savings rate −0.00931* (0.00477) −0.00757 (0.00502) −0.00699 (0.00489)
Govt. expenditure 0.0120*** (0.00392) 0.0143*** (0.00364) 0.00365 (0.00542)
Population over 65 0.177 (0.574) 0.318 (0.494) −0.136 (0.444)
Lag (1) pharmaceutical exp. 0.573*** (0.0839)
Year FE Yes Yes Yes Yes Yes
Country FE Yes Yes Yes Yes Yes
Observations 1,152 789 1,063 551 970
R‐squared 0.486 0.325 0.468 0.358 0.657
First stage F‐stat 7.42 5.35 11.03 8.57 10.65
p value 0.007 0.023 0.0012 0.004 0.0015
Kleibergen‐Paap LM statistic 6.12 4.60 7.30 5.47 8.22
p value 0.0133 0.032 0.0069 0.0193 0.0041
Hausman test statistic 17.328 204.099 77.100 67.704 181.19
p value 0.0000 0.0000 0.0000 0.0000 0.0000
Endogeneity test 1.58 2.52 2.86 2.09 4.21
p value 0.2083 0.1119 0.0905 0.1476 0.0401
Number of countries 96 72 120 73 110
Note. The DV in all columns is public pharmaceutical expenditure per capita. All estimates are IV estimates. Column (1) shows estimates using a balanced sam-
ple; column (2) shows estimates after excluding outliers from the balanced panel identified using the Hadi procedure; column (3) shows estimates after inclu-
sion of relevant controls in the full sample; column (4) shows estimates after inclusion of controls and exclusion of outliers from the full sample; column (5)
shows estimates from a dynamic model that includes the first lag of pharmaceutical expenditure and thereby accounts for inertia in pharmaceutical spending.
Health expenditure here refers to all other health spending excluding public pharmaceutical spending. DV: dependent variable; GDP: gross domestic product;
IV: instrumental variable.
***p < 0.01. **p < 0.05. *p < 0.1.
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health economics literature would presume,9 it is in line with some of the other literature that assesses the effect of gov-
ernment spending on economic growth (Devarajan et al., 1996; Miller & Russek, 1997). Next, we assess the robustness of
the results in a similar way as we did in Table 3. Analyzing only a balanced sample of countries, excluding outliers using
the Hadi (1992) procedure, and including further control variables, we find the same result. In each of these tests, public
pharmaceutical expenditure is negatively related to GDP per capita.
4.4 | Intertemporal effects
Given the typical short term thinking of policy makers, we have so far focused on an analysis of concomitant effects. How-
ever, it is plausible that the relationship between GDP and pharmaceutical spending is intertemporal in nature. We there-
fore assess whether there is any effect of lagged GDP on current pharmaceutical expenditure and that of lagged
pharmaceutical expenditure on current GDP. We show results for up to three lags of GDP and pharmaceutical
TABLE 4 Public pharmaceutical expenditure per capita and GDP per capita
Variables
(1) (2) (3) (4) (5) (6)
Overall Balanced panel Outliers (O) Controls (C) O + C C + L
GDP per capita
(natural log)
GDP per capita
(natural log)
GDP per capita
(natural log)
GDP per capita
(natural log)
GDP per capita
(natural log)
GDP per capita
(natural log)
Pharmaceutical exp. −0.0915**
(0.0400)
−0.0978***
(0.0363)
−0.158***
(0.0526)
−0.0842***
(0.0242)
−0.071*** (0.0239) −0.112***
(0.0313)
Health expenditure 0.244*** (0.0542) 0.166** (0.0688) 0.260*** (0.0470)
Life expectancy −0.712 (0.498) −0.743 (0.585) −0.251 (0.566)
Capital formation 0.00444***
(0.00103)
0.00490***
(0.00157)
0.00251*
(0.00138)
Savings rate 0.00176 (0.00139) 0.00351* (0.00173) 0.00296*
(0.00168)
Govt. expenditure −0.000201
(0.00119)
−0.000728
(0.001645)
0.000493
(0.00186)
Population over 65 0.328** (0.135) 0.336 (0.221) 0.311*** (0.118)
Lag (1) pharmaceutical
exp.
0.108*** (0.0322)
Year FE Yes Yes Yes Yes Yes Yes
Country FE Yes Yes Yes Yes Yes Yes
Observations 1,389 1,152 789 1,063 551 970
R‐squared 0.479 0.564 0.443 0.655 0.603 0.657
First stage F‐stat 395.2 366.1 146.6 372.7 605.2 385.63
p value 0.000 0.000 0.000 0.000 0.000 0.000
Kleibergen‐Paap LM
statistic
32.14 24.26 15.94 22.00 12.45 14.47
p value 0.0000 0.0000 0.0001 0.0000 0.0004 0.0001
Endogeneity test 10.77 20.06 16.43 27.98 17.35 29.56
p value 0.0010 0.0000 0.0001 0.0000 0.0000 0.0000
No. of countries 136 96 72 120 73 110
Note. The DV in all columns is GDP per capita (natural log). All estimates are IV estimates. Column (1) shows estimates of the effect of public pharmaceutical
expenditure per capita on GDP per capita (natural log) for the full sample. Column (2) shows estimates using a balanced panel; column (3) shows IV estimates
after excluding outliers from the balanced panel identified using the Hadi procedure; column (4) shows estimates after inclusion of relevant controls in the full
sample; column (5) shows estimates after inclusion of controls and exclusion of outliers from the full sample; column (6) shows estimates from a dynamic model
that includes the first lag of pharmaceutical expenditure and thereby accounts for inertia in pharmaceutical spending. Health expenditure here refers to all other
health spending excluding public pharmaceutical spending. DV: dependent variable; GDP: gross domestic product; IV: instrumental variable.
***p < 0.01. **p < 0.05. *p < 0.1.
9To the extent that health expenditures improve health, and health improves productivity, health expenditures should be positively related to eco-
nomic growth (Bhargava, Jamison, Lau, & Murray, 2001; Bloom et al., 2004; Bloom & Canning, 2000). A recent study examining the direct link
between public health spending and economic growth has found a positive relationship between the two (Halıcı‐Tülüce, Doğan, & Dumrul, 2016).
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expenditure in Table 5.10 Although the point estimates of the effect of GDP per capita on pharmaceutical expenditure are
quantitatively similar, they are statistically significant at a 10% level. Pharmaceutical expenditure, however, continues to
show similar effects on GDP as before, both quantitatively and qualitatively. We discuss the negative effect of pharmaceu-
tical spending on GDP in more detail in the conclusion section and provide several explanations in support of our
findings.
So far, our results are consistent regarding the different specifications and sensitivity tests. However, concerns around
the validity of the instrument may remain. We address such concerns in the next section related to instrument validity.
5 | INSTRUMENT VALIDITY
The first stage F‐statistics clearly support the notion of relevance of the instrument. However, validity (exclusion restric-
tion) is not directly testable. It is therefore worthwhile to discuss issues related to validity of the instrument and potential
threats to validity. We show unadjusted and adjusted (partial) correlation coefficients in Tables A2a and A2b. When we
look at the partial correlations, we find a strong relationship between GDP per capita and pharmaceutical expenditure.
However, the partial correlation between tourist receipts and pharmaceutical expenditure is virtually zero; these descrip-
tive findings therefore support the relevance and validity arguments for our instrument. Further, although it seems plau-
sible to us that tourist receipts (spending by international visitors on food, travel, etc.) should not be related to public
pharmaceutical expenditures of the host country directly other than through GDP, one can argue that medical tourism
could be a potential source of contamination. Nevertheless, we argue that even if this were a likely source of correlation
between the instrument and pharmaceutical spending, it seems plausible to presume that this spending will not be
reflected in the public pharmaceutical expenditure of a country. In addition, it may also be argued that tourism itself
may depend on the underlying health conditions of a country. For instance, an outbreak of a diseasemay affect the number
of tourists visiting a country and therefore be related to GDP, health, and health expenditure. A priori one can expect dis-
ease outbreaks to be positively related to pharmaceutical expenditures (as they are likely to increase utilization of health
services) and negatively related to GDP. In this scenario, if anything, our results would be an underestimate of the true
effect. As unlikely as we perceive these effects to be on average, we collect data on disease outbreaks from 1996 up to
the years in our sample.11 We first show in column (1) of Table 6 that there is no systematic relationship between disease
TABLE 5 Intertemporal effects of GDP per capita and public pharmaceutical expenditure
Panel A: Lagged effect of GDP per capita on public pharmaceutical expenditures
Variables
(1) (2) (3)
Lag 1 year Lag 2 years Lag 3 years
GDP per capita (natural log) 1.856* (1.073) 2.182* (1.126) 2.083* (1.184)
Panel B: Lagged effect of public pharmaceutical expenditures on GDP per capita
Variables
(1) (2) (3)
Lag 1 year Lag 2 years Lag 3 years
Pharmaceutical exp. −0.147*** (0.0415) −0.143*** (0.0373) −0.136*** (0.0361)
Year FE Yes Yes Yes
Country FE Yes Yes Yes
Observations 1,056 960 864
No. of countries 96 96 96
Note. Panel A (columns [1] to [3]) shows the lagged effect of GDP per capita (natural log) on public pharmaceutical expenditure using 1‐year to 3‐year lags of
GDP per capita. Panel B shows the reverse effect, that is, of public pharmaceutical expenditure on GDP per capita using 1‐year to 3‐year lags of public phar-
maceutical expenditure. All models include country and year fixed effects and a balanced sample of countries. GDP: gross domestic product.
***p < 0.01. **p < 0.05. *p < 0.1.
10We lose almost 30% of our sample by the fourth lag of pharmaceutical expenditure. Hence, due to data limitations, the analysis is restricted to
three lags.
11The data for disease outbreaks per country per year are from Google's public database on infectious disease outbreaks taken from HealthMap.org,
Harvard Medical School. Due to missing data on most of the countries, we have a smaller sample in comparison with our main results. The data
are available from https://www.google.com/publicdata/explore?ds=gh9ira29bjcpl_&ctype=l&strail=false&nselm=h&met_y=num_outbreaks&scale_
y=lin&ind_y=false&rdim=whoregion&idim=whoregion%3AAfrica%3AAmericas%3AEastern+Mediterranean%3AEurope%3ASouth‐East+Asia%3AWestern
+Pacific&tdim=true&tstart=&hl=en&dl=en [Last accessed February 23, 2018].
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outbreaks in a country and tourist receipts earned by the country, indicating that disease outbreaks are unlikely to affect
tourism in our sample and thereby contaminate our IV strategy. Then, in column (2), we show the IV estimate of the effect
of GDP per capita on public pharmaceutical expenditure per capita controlling for disease outbreaks. Our point estimates
are robust to the inclusion of this control variable. Column (3) shows the effect of pharmaceutical expenditure onGDP con-
trolling for disease outbreaks. We continue to find a negative and significant (at the 10% level) effect of pharmaceutical
spending on GDP.
6 | EFFECT HETEROGENEITY
The fixed effects in our analysis ensure that long‐standing differences between countries do not bias the estimates in any
way, that is, differences pertaining to the country level such as preferences for spending on health care and production
functions play no role. However, it is likely that the elasticity of pharmaceutical expenditure differs across countries as is
observed in past literature on health expenditures. Prior literature that investigates elasticity of health expenditure
usually assesses heterogeneity by simply segmenting countries into income groups, development levels, health
spending, and time periods (Blazquez‐Fernandez, Cantarero, & Perez, 2014; Farag et al., 2012). We extend the
investigation of effect heterogeneity in several ways by considering (a) different quantiles of the response variables
and (b) politico‐economic freedom of countries.12
6.1 | Income groups
First, similar to prior research on determinants of health expenditure, we investigate heterogeneity by income group.
Columns (1) and (3) of Table 7.1 show the estimates of the effect of GDP per capita on public pharmaceutical expen-
diture for high‐ and low‐income countries, respectively. The effect is significant only for the group of high‐income
countries where the elasticity exceeds unity; however, it is not significant for low‐income countries. Columns (2)
and (4) show the corresponding estimates of the effect of public pharmaceutical expenditure on GDP per capita.
The estimates are negative, significant at a 5% level only for low‐income countries and not significant at any conven-
tional level for high‐income countries. It is important to note here that due to sample size issues, we classified high‐
income and upper middle‐income countries together as high‐income countries. Similarly, we classified low‐income
and lower middle‐income countries together as low‐income countries. We therefore need to bear in mind that not
all high‐income countries and not all low‐income countries are at the same level of GDP or pharmaceutical spending.
For example, in our sample in 2006, the difference between GDP per capita of the country with the highest GDP
TABLE 6 Instrument validity
Variables
(1) (2) (3)
Tourist receipts Pharmaceutical expenditure GDP per capita (natural log)
No. of outbreaks −0.0500 (0.0353) −0.0183 (0.0272) 0.0153 (0.0107)
GDP per capita (natural log) 2.251*** (0.484)
Pharmaceutical exp. −0.0739* (0.0431)
Year FE Yes Yes Yes
Country FE Yes Yes Yes
Observations 797 592 797
R‐squared 0.343 0.182 −0.213
No. of countries 71 65 71
Note. Column (1) shows the relationship between disease outbreaks in a country and tourist receipts. Column (2) shows the IV estimates of the effect of GDP per
capita (natural log) on public pharmaceutical expenditure per capita controlling for disease outbreaks. Column (3) shows the IV estimates of the effect of public
pharmaceutical expenditure per capita on GDP per capita (natural log) controlling for disease outbreaks. GDP: gross domestic product; IV: instrumental
variable.
***p < 0.01. **p < 0.05. *p < 0.1.
12We are grateful to a reviewer for recommending these strategies that have helped enrich the analysis.
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(Luxembourg) in the high‐income group and the country with the lowest GDP (Fiji) in the upper middle‐income group
was as much as U.S. $99,328. Similarly, the difference is as much as U.S. $5,345 between the country with the highest
GDP (Colombia) in the lower‐middle income group and the lowest GDP country (Ethiopia) in the low‐income group.
There is high variation in both GDP and pharmaceutical expenditure within the two income groups and therefore
combining these countries in the same group may not provide an accurate picture. We therefore employ additional
strategies to assess heterogeneity, as described next.
6.2 | IV quantile regressions
Werecognize the importance of going beyond conditionalmeans, something that the empirical economics literaturemakes
a compelling case for (Koenker &Hallock, 2001), and adopt an IV quantile regression approach to assess the effects of GDP
and pharmaceutical expenditure. Quantile regressions are robust to nonnormal errors and outliers. In addition, they allow
us to estimate the impact of GDP per capita on the entire distribution of pharmaceutical expenditure and vice versa.
Table 7.2 shows the results of the IV quantile regressions. Panel A shows the results of the income elasticity of
pharmaceutical expenditure at the 10th, 25th, 50th, 75th, and 90th quantiles of pharmaceutical expenditure. We find
that the elasticity systematically decreases as we move to higher quantiles of expenditure. For countries that are at the
lower end of the distribution, that is, spend very little on pharmaceutical expenditure, a 1% increase in GDP per capita
leads to an approximately 2% increase in pharmaceutical expenditures. However, for countries at the upper end of the
distribution we find that the increase in pharmaceutical expenditure in response to an increase in GDP per capita is
near unity. The results seem plausible given that countries with limited spending on pharmaceuticals increase spend-
ing with increases in GDP, because they have not yet reached the “flat part of the curve” of medical spending, that is,
marginal productivity of expenditure may still be increasing (Farag et al., 2012). However, countries that are already at
the high end of spending face diminishing returns to health spending and, hence, contain health spending.
The difference in the income elasticity of pharmaceutical expenditure between an analysis by pharmaceutical expen-
diture (quantile regressions) and an analysis by income is noteworthy because countries spending less on pharmaceuticals
are also poorer countries; Table A3 in the appendix shows the percentage of high‐ and low‐income countries at each
quantile of pharmaceutical spending. However, there is significant between‐country heterogeneity even within an income
group. For example, between‐country variation in GDP per capita in the low‐income group is as much as $1,234.63. This
heterogeneity between countries reduces to half for low‐income countries with low spending, that is, lowest quantile of
pharmaceutical expenditure, thus pointing towards the role of spending. Therefore, a simple classification into high‐
and low‐income groups does not show the complete picture; quantile regressions enrich our understanding of the results
TABLE 7.1 Effect heterogeneity: Income groups
High income Low income
(1) (2) (3) (4)
Variables
Pharmaceutical
expenditure
GDP per capita
(natural log)
Pharmaceutical
expenditure
GDP per capita
(natural log)
GDP per capita (natural log) 1.766*** (0.849) 1.319 (1.017)
Pharmaceutical exp. −0.136 (0.092) −0.098*** (0.038)
Year FE Yes Yes Yes Yes
Country FE Yes Yes Yes Yes
Observations 797 797 592 592
R‐squared 0.531 0.445 0.315 0.481
First stage F‐stat 24.81 56.55 4.28 474.10
p value 0.000 0.000 0.042 0.000
Kleibergen‐Paap LM statistic 6.58 15.35 3.66 15.37
p value 0.0103 0.0001 0.0557 0.0001
Endogeneity test 2.221 4.586 2.081 10.677
p value 0.1362 0.0322 0.1491 0.0011
Number of countries 71 71 65 65
Note. The DV in columns (1) and (3) is public pharmaceutical expenditure per capita; in columns (2) and (4), it is GDP per capita (natural log). Columns (1) and
(2) show IV estimates for high‐income countries whereas columns (3) and (4) show IV estimates for low‐income countries. GDP: gross domestic product; IV:
instrumental variable.
***p < 0.01. **p < 0.05. *p < 0.1.
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and reveal that the existing spending level is important for explaining heterogeneity. Although prior literature that anal-
yses overall health expenditures finds an income elasticity of less than unity over the entire distribution (Tian, Gao, &
Yang, 2016), results for specific type of expenditure such as pharmaceuticals thus show a different picture.
With respect to the impact of pharmaceutical spending on GDP per capita, we find that the results are negative and
significant only for the 25th, 50th, and 75th quantiles. These results imply that pharmaceutical expenditure does not have
any impact on GDP at the lowest and the highest end of the distribution, that is, in the poorest and richest countries. These
results are to some extent similar to the results we observewith the income groupswhere the richer countries do not show a
significantly negative effect of pharmaceutical spending.We posit that the budget constraint these countries face relative to
middle‐ and low‐income countries is not as stringent in that, they invest significantly in other productive types of govern-
ment activities as well. As such, the investment diversion that low‐income countries face might be higher.
6.3 | Politico‐economic situation
As the World Health Report, 2000, argues, health law enforcement and political‐economic conditions play an important
role in shaping national policies on health care that may be either health promoting or health restricting. For example,
trade embargoes in countries can restrict import–export of essential medicines, thereby affecting health outcomes.
Hence, the degree of political freedom in a country may determine health policies and subsequent health spending.
As such, two countries may grow apart by their income levels; yet it is not income but political and economic freedom
that determines spending on pharmaceuticals.13
We therefore assess heterogeneity in the effects by political‐economic situation (see Table 7.3) using the EFW index
from the Fraser Institute.14 For details on the EFW index, we refer readers to https://www.fraserinstitute.org/. We use
data on the overall score along with scores on civil and political rights that classify countries as economically “free” or
“not free.”We find that GDP per capita has a significant impact on pharmaceutical spending only in countries classified
as “free.” It is not significant for countries classified as “not free.” This implies that for these countries, it is not GDP, but
the political environment that matters. In contrast, we find that the impact of pharmaceutical expenditure has a signif-
icantly negative effect only in countries that are “not free.” It is not significant for countries classified as “free.”
Overall, heterogeneity of countries with respect to economic development, pharmaceutical spending, and political
environment plays an important role. As the results show, low‐income countries respond differently to an increase in
GDP and an increase in health spending compared with high‐income countries. Most of the low‐income countries in
our sample are also classified as “not free” (75%), whereas most of the high‐income countries are classified as “free”
(80%). This heterogeneity in the effects can have important implications for pharmaceutical policy and regulation,
which we discuss in Section 8.
TABLE 7.2 Effect heterogeneity: Quantile IV regressions
Panel A: Effect of GDP per capita on public pharmaceutical expenditures
(10th) (25th) (50th) (75th) (90th)
Variables
GDP per capita (natural log) 1.957*** (0.286) 1.320*** (0.153) 1.205*** (0.121) 1.056*** (0.0781) 1.069*** (0.0565)
Panel B: Effect of public pharmaceutical expenditures on GDP per capita
(10th) (25th) (50th) (75th) (90th)
Variables
Pharmaceutical exp. −0.0290 (0.0206) −0.0486*** (0.00772) −0.0490*** (0.0121) −0.0509*** (0.0158) −0.0398 (0.0265)
Year FE Yes Yes Yes Yes Yes
Country FE Yes Yes Yes Yes Yes
Observations 1,389 1,389 1,389 1,389 1,389
No. of countries 136 136 136 136 136
Note. The DV in panel A is public pharmaceutical expenditure per capita, and in panel B, it is the natural log of GDP per capita. The coefficients represent
estimates from IV quantile regressions at the 10th, 25th, 50th, 75th, and 90th quantile of the respective dependent variable as indicated. All regressions include
year fixed effects and country fixed effects. GDP: gross domestic product; IV: instrumental variable.
***p < 0.01. **p < 0.05. *p < 0.1.
13We are grateful to a referee for pointing this out.
14Data are available openly from https://www.fraserinstitute.org/economic‐freedom/dataset?min‐year=1970&max‐year=2015&filter=0&date‐type=
range&geozone=world&page=dataset.
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7 | EXPLAINING THE NEGATIVE EFFECT OF PUBLIC PHARMACEUTICAL
EXPENDITURE
An obvious question that arises from the results concerns the negative effect of public pharmaceutical expenditure on
GDP per capita, that is, how the negative effect can be explained. Theoretically, Ram (1986) suggests that government
size can be growth reducing; empirically, findings of some of the prior literature support this notion (Barro, 1991;
Landau, 1983). We draw on this literature and provide arguments that are both general to government spending
and specific to pharmaceutical spending. Government size can be harmful for growth due to inefficiency, regulatory
costs, and distorted economic incentives arising out of government fiscal policies (Ram, 1986). Distortionary taxes to
finance government spending may negatively affect savings and hence growth (Barro, 1991). If public spending crowds
out private investment, and if government spending is on inefficient and unproductive activities, it can impinge neg-
atively on growth (Afonso & Furceri, 2010). Financing of government spending by means of increased taxation may
have negative spillovers to the economy (Asimakopoulos & Karavias, 2016).
Another reason through which public spending on pharmaceuticals affects GDP negatively may be an investment
diversion effect. With respect to health spending, others (Acemoglu & Johnson, 2007; Ashraf et al., 2008) have found
that it takes a long time for health‐related economic returns to be witnessed. Even if we witness health benefits that
translate into economic returns contemporaneously, they might not be large enough to justify the disproportionate
spending, which is an opportunity cost in itself and diverts resources away from potentially more productive sources
of public expenditure such as transport and infrastructure spending (Easterly & Rebelo, 1993; Kelley, 1988). Third, most
countries have a significant demand for imported pharmaceutical products, and spending a lot on imported drugs may
lead to a downward multiplier effect in the economy. For example, in the Unites States, direct imports of pharmaceu-
ticals rose from $15.4 billion out of the $63.3 billion pharmaceutical sales in 1998 to around $68 billion out of the $151
billion sales in 2012 (Werling et al., 2014). Finally, the method of financing government expenditures might play a cru-
cial role in determining the relationship between spending and growth; debt financed increases in health spending can
have negative effects on economic growth (Ahmed & Miller, 1999). Increased government borrowing and higher taxes
to finance health expenditures can be detrimental to economic growth in that it reduces income for private spending. A
large part of health expenditure is indeed financed by taxes or social insurance contributions (Gerdtham & Jönsson,
2000). In addition, spending on ineffective drugs (in terms of both cost and illness) results in unproductive expenditure,
which does not contribute to the economy. This may be particularly true for less developed and politico‐economically
unfree countries that not only lack efficient allocative mechanisms but also face accessibility problems to high quality
medicines (Kyle & McGahan, 2012). Our results are particularly significantly negative for such less developed and poor
TABLE 7.3 Effect heterogeneity: Politico‐economic freedom
Panel A: Effect of GDP per capita on public pharmaceutical expenditures
Civil liberty Political rights Overall score
(1) (2) (3) (4) (5) (6)
Free Not free Free Not free Free Not free
GDP per capita
(natural log)
1.573*** (0.603) 1.486 (0.937) 1.854*** (0.712) 1.606 (1.212) 1.479** (0.619) 1.361 (0.972)
Panel B: Effect of public pharmaceutical expenditures on GDP per capita
Civil liberty Political rights Overall score
(1) (2) (3) (4) (5) (6)
Free Not free Free Not free Free Not free
Pharmaceutical exp. −0.0292 (0.0260) −0.157** (0.0660) −0.0461 (0.0296) −0.192** (0.0837) −0.00344 (0.0232) −0.151** (0.0636)
Year FE Yes Yes Yes Yes Yes Yes
Country FE Yes Yes Yes Yes Yes Yes
Observations 654 733 791 591 780 601
No. of countries 66 89 79 78 78 79
Note. The DV in panel A is Public pharmaceutical expenditures, and in Panel B, it is GDP per capita. The EFW index is used to classify countries as “free” and “not
free” based on civil liberties (columns [1] and [2]), political rights (columns [3] and [4]), and an overall score (columns [5] and [6]). All regressions include year fixed
effects and country fixed effects. DV: dependent variable; EFW: Economic Freedom of the World; GDP: gross domestic product; IV: instrumental variable.
***p < 0.01. **p < 0.05. *p < 0.10.
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countries. Pharmaceuticals covered by public resources in these countries may not be cost‐saving or even cost‐effective
because public resources may be misdirected. Hence, the allocation of government expenditures may not be rational in
this sense. As a result, inefficient spending coupled with a stringent budget constraint raises the opportunity cost and
reduces productive returns much more in these countries. Although we are unable to investigate specifically each mech-
anism due to data unavailability, we leave this avenue open for future research. We discuss the implications of our find-
ings for policy in the next section.
8 | CONCLUSION
This paper answers two questions that are both important and strongly debated in the health economics literature. First, it
assesses the income elasticity of medical spending focusing on public pharmaceutical expenditures. Second, it assesses the
effect of public pharmaceutical spending on income measured by GDP per capita. To this end, the paper employs a two‐step
IV procedure using data for 136 countries from 1995 to 2006 and answers both research questions within the same econo-
metric framework. Briefly, our IV estimates suggest that the least squares regression model significantly underestimates the
response of public pharmaceutical spending to GDP per capita, and once endogeneity is accounted for, public pharmaceu-
tical expenditure shows an income elasticity that is greater than unity. Further, once the reverse causal effect of GDP on
pharmaceutical spending is accounted for, public pharmaceutical spending itself has a negative effect on GDP per capita.
Heterogeneity of countries with respect to economic development, pharmaceutical spending, and politico‐economic envi-
ronment plays an important role in the understanding of these results and their implications for health policy. Overall,
countries that spend little on pharmaceuticals show an income elasticity above one, whereas countries that spend a lot
are unitary elastic. Countries that are politico‐economically “free” in our analysis show elasticity greater than unity,
whereas countries that are “not free” show no significant relationship with income. On the contrary, pharmaceutical spend-
ing itself has a negative impact on GDP in “unfree” countries and countries at the lower end of the distribution of GDP.
Given these results, the question is how do they inform health care policy. As Acemoglu et al. (2013) point out,
understanding the role of income in the rise of health expenditures is important for forecasting the evolution of health
expenditures and analyzing the social optimality of health spending. Further, an assessment of the elasticity of phar-
maceutical spending is crucial for policy in that it will aid policy makers in deciding whether to intervene in the mar-
ket or to let market forces play a role in improving welfare. Finally, our findings show that countries that spend little
on pharmaceuticals have an income elasticity greater than one; which begs the question—are we achieving conver-
gence in pharmaceutical spending across the world.15 Concerning the negative effect of pharmaceutical spending on
GDP, the results point towards a need for improving efficiency and effectiveness of medical spending as well as limit-
ing waste. Although “irrational” use of medicines is a problem in both low‐ and high‐income countries, in developed
countries, routine monitoring and strong electronic systems limit wasteful spending to a certain extent. In developing
countries, however, such monitoring systems are not available, resulting in more than 60% of the patients in the public
sector not being treated according to appropriate guidelines (WHO, 2011). Furthermore, even if medicines are pre-
scribed appropriately, patient adherence is weak with over 80% drugs being dispensed by unqualified personnel and
about one‐third of patients lacking knowledge on how to take medicines (WHO, 2011). Therefore, despite incurring
costs, medicines may not translate into health benefits.
Furthermore, high‐income countries have strong regulations such as reference pricing, national or regional procure-
ment contracts and reimbursement policies that provide them with a certain degree of control over prices. As a result,
there is less differential between originator brands and lowest price generics than in low‐income countries where the
difference may be over 300% (WHO, 2011). Therefore, the higher prices that low‐income countries are subjected to fur-
ther raise the opportunity cost of spending on pharmaceuticals.
Improving allocative efficiency of government budgets taking into account the opportunity costs of spending on
health care, and investing optimally in other areas are crucial steps for the sustainability of fiscal budgets. An
important policy implication due to the heterogeneity in the results is that encouraging the uptake of cost‐effective
medicines in less developed countries may be key for efficient health spending. Revill et al. (2014) argue that current
cost‐effectiveness thresholds set by the WHO are not adequate as they impose opportunity costs under budget
constraints. Given our findings of the negative effect on growth, this becomes important for long‐term sustainability
15Note that Farag et al. (2012) find lower income elasticity of health spending and argue to the contrary that convergence in health and health spend-
ing is unlikely anytime soon.
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of health care systems in these countries. On a similar note, policy should be geared towards price control so that more
can be achieved with the same level of spending without having to reduce volume (which is not an option in low‐
income countries anyway given the low level of spending).
The results based on the politico‐economic freedom mean that greater politico‐economic freedom may help coun-
ter the negative effect of health spending by improving within‐ and cross‐border pharmaceutical trade, thus increas-
ing access to essential medicines. This may improve the marginal productivity of health expenditure. Also, providing
subsidies and encouraging local R&D to reduce dependence on imported and expensive pharmaceuticals may help
counter the negative multiplier effect in the economy. Finally, it needs to be acknowledged that even if economic
growth is negative and pharmaceutical spending is wasteful to some degree, there may be reasons beyond economic
growth to increase public funds for pharmaceuticals, for example, a reduction in inequality in access to
pharmaceuticals.
Before we conclude, it is important to mention a few caveats of the analysis and provide recommendations for
future research related to this topic. First, our analysis largely addresses contemporaneous effects. The short‐term
perspective is of particular interest to policy makers as they generally have a short planning horizon. This is similar
to the perspective of a budget impact analysis, a standard tool for estimating the financial consequences of adopting
new health interventions. However, long‐run effects cannot be ruled out, and hence, we analyze lagged effects within
the limits of data availability. As longer time series data becomes available, future work should look into long‐run
elasticities of health spending and the long‐run effect of health spending on income. As a word of caution, even
in the long‐term increased public pharmaceutical expenditure may not lead to economic growth because of the
reasons mentioned previously and because savings in health expenditures may not be realized (see, e.g., Shroufi
et al., 2013, and Horton et al., 2017). Second, we consider public pharmaceutical spending because it forms a major
part of total health expenditure and is exposed to many regulations. Needless to say, that future work should
consider different types of health spending such as preventive and rehabilitative expenditures. Finally, we consider
pharmaceutical expenditure in its final form ignoring that it is a combination of price and quantity (Lu, Hernandez,
Abegunde, & Edejer, 2011). To the extent that prices reflect the innovativeness of a drug or a drug being branded/
generic, and quantity reflects the disease burden of the country, analyzing the elasticity by separating expenditures
into these components could provide interesting insights for policy. As better data become available in the future,
this could be a potential question for researchers to pursue.
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APPENDIX A
Appendix A.1 xxx
TABLE A1 Countries and number of observations per country
Country Observations Country Observations Country Observations
Albania 4 Fiji 12 Netherlands 12
Algeria 12 Finland 12 New Zealand 12
Antigua and Barbuda 12 France 12 Nicaragua 12
Argentina 12 Gabon 11 Niger 2
Armenia 12 Georgia 10 Norway 12
Australia 12 Germany 12 Oman 2
Austria 12 Greece 12 Pakistan 7
Azerbaijan 12 Grenada 12 Panama 12
The Bahamas 12 Guatemala 12 Papua New Guinea 12
Bahrain 12 Guinea 2 Paraguay 12
Bangladesh 12 Guyana 12 Peru 12
Barbados 12 Haiti 11 Philippines 12
Belarus 12 Honduras 12 Poland 12
Belgium 12 Hungary 12 Portugal 12
Belize 12 Iceland 12 Russian Federation 12
Benin 2 India 12 Rwanda 2
Bhutan 10 Indonesia 12 Samoa 12
Bolivia 12 Ireland 12 Senegal 12
Bosnia and Herzegovina 4 Israel 12 Serbia 5
Brazil 12 Italy 12 Singapore 7
Brunei Darussalam 6 Jamaica 12 Slovak Republic 12
Bulgaria 12 Japan 12 Slovenia 12
Burkina Faso 7 Jordan 3 Solomon Islands 8
Cabo Verde 12 Kazakhstan 12 Spain 12
Cambodia 12 Kenya 7 Sri Lanka 12
Cameroon 7 Kiribati 8 St. Kitts and Nevis 12
Canada 12 Korea, Rep. 12 St. Lucia 12
Central African Republic 12 Kuwait 2 St. Vincent and the Grenadines 12
Chad 8 Kyrgyz Republic 12 Suriname 12
Chile 12 Lao PDR 12 Sweden 12
China 12 Latvia 12 Switzerland 12
Colombia 12 Lesotho 3 Thailand 12
Costa Rica 12 Lithuania 12 Tonga 10
Croatia 12 Luxembourg 12 Trinidad and Tobago 12
Cyprus 12 Macedonia, FYR 12 Tunisia 4
Czech Republic 12 Malawi 4 Turkey 9
Denmark 12 Malaysia 12 Uganda 8
Djibouti 7 Maldives 6 Ukraine 12
Dominica 12 Mali 7 United Kingdom 12
Dominican Republic 12 Malta 12 United States 12
Ecuador 12 Mexico 12 Uruguay 12
El Salvador 12 Moldova 10 Uzbekistan 7
Equatorial Guinea 7 Mongolia 12 Venezuela, RB 4
Estonia 12 Myanmar 12 Vietnam 4
Ethiopia 2 Nepal 12 Yemen, Rep. 3
Zambia 7
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TABLE A2a Pearson's correlation coefficients between public pharmaceutical expenditure, GDP per capita, and tourist receipts
Public pharmaceutical
expenditure
GDP per capita
(natural log)
GDP per capita (natural log) 0.9193
p value (0.0000)
Tourist receipts 0.6027 0.6751
p value (0.0000) (0.0000)
Note. The table shows Pearson's correlations. The p value is reported in parentheses below the correlation coefficient. GDP: gross domestic product.
TABLE A2b Partial correlations between public pharmaceutical expenditure, GDP per capita, and tourist receipts
Public pharmaceutical
expenditure
GDP per capita
(natural log)
GDP per capita (natural log) 0.8704 —
p value (0.0000) —
Tourist receipts −0.0616 0.3854
p value (0.0217) (0.0000)
Note. The table shows partial correlations. The p value is reported in parentheses below the correlation coefficient. GDP: gross domestic product.
TABLE A3 Percentage of high‐ and low‐income group of countries at quantiles of pharmaceutical expenditure
Quantiles of public pharmaceutical expenditure
1 (%) 2 (%) 3 (%) 4 (%) 5 (%)
High‐income group 2.13 29.03 60.79 96.77 100.00
Low‐income group 97.87 70.97 39.21 3.23 0.00
22 SHAIKH AND GANDJOUR
